Faculty Collaboration Database

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treat Rev 2015 Sep;41(8):699-706

Date

07/04/2015

Pubmed ID

26138514

DOI

10.1016/j.ctrv.2015.06.004

Scopus ID

2-s2.0-84941023230 (requires institutional sign-in at Scopus site)   14 Citations

Abstract

Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.

Author List

Ikeda S, Hansel DE, Kurzrock R

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Carcinoma, Transitional Cell
DNA-Binding Proteins
Disease Management
Histone Demethylases
Humans
Immunotherapy
Molecular Targeted Therapy
Mutation
Neoplasm Proteins
Nuclear Proteins
Therapies, Investigational
Transcription Factors
Urologic Neoplasms